{
  "fullName": "Mitch Dowsett",
  "slug": "mitch-dowsett",
  "title": "MD",
  "specialty": "Breast Cancer Endocrine Therapy",
  "geography": {
    "country": "United Kingdom",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "UNRANKED",
  "rankingScore": 28,
  "hIndex": 146,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Steroidal aromatase inhibitors are a class of drugs that are mostly used for treating breast cancer in postmenopausal women. High levels of estrogen in breast tissue increases the risk of developing breast cancer and the enzyme aromatase is considered to be a good therapeutic target when treating breast cancer due to it being involved in the final step of estrogen biosynthetic pathway and also its inhibition will not affect production of other steroids. Aromatase Inhibitors are classified into two categories based on their structure, nonsteroidal and steroidal; the latter resemble the structure of androstenedione. Steroidal aromatase inhibitors irreversibly inhibit the enzyme by binding covalently to the binding site of aromatase so the substrate cannot access it.",
  "aiSummary": "Mitch Dowsett is a breast cancer endocrine therapy specialist with an H-index of 146 at Royal Marsden Hospital (Faculty). Has been published in New England Journal of Medicine, The Lancet, Science. Based in United Kingdom.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Royal Marsden Hospital",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Breast Cancer Endocrine Therapy"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2005,
      "citationCount": 5063,
      "doi": "10.1056/nejmoa052306",
      "sourceUrl": "https://doi.org/10.1056/nejmoa052306",
      "verified": true
    },
    {
      "title": "American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2006,
      "citationCount": 4453,
      "doi": "10.1200/jco.2006.09.2775",
      "sourceUrl": "https://doi.org/10.1200/jco.2006.09.2775",
      "verified": true
    },
    {
      "title": "American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2010,
      "citationCount": 4200,
      "doi": "10.1200/jco.2009.25.6529",
      "sourceUrl": "https://doi.org/10.1200/jco.2009.25.6529",
      "verified": true
    },
    {
      "title": "Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update",
      "journal": "Journal of Clinical Oncology",
      "year": 2013,
      "citationCount": 3998,
      "doi": "10.1200/jco.2013.50.9984",
      "sourceUrl": "https://doi.org/10.1200/jco.2013.50.9984",
      "verified": true
    },
    {
      "title": "Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update",
      "journal": "Journal of Clinical Oncology",
      "year": 2018,
      "citationCount": 2324,
      "doi": "10.1200/jco.2018.77.8738",
      "sourceUrl": "https://doi.org/10.1200/jco.2018.77.8738",
      "verified": true
    },
    {
      "title": "Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer",
      "journal": "The Lancet",
      "year": 2005,
      "citationCount": 2265,
      "doi": "10.1016/s0140-6736(04)17666-6",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(04)17666-6",
      "verified": true
    },
    {
      "title": "Patient-derived organoids model treatment response of metastatic gastrointestinal cancers",
      "journal": "Science",
      "year": 2018,
      "citationCount": 1923,
      "doi": "10.1126/science.aao2774",
      "sourceUrl": "https://doi.org/10.1126/science.aao2774",
      "verified": true
    },
    {
      "title": "American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer",
      "journal": "Archives of Pathology & Laboratory Medicine",
      "year": 2007,
      "citationCount": 1840,
      "doi": "10.5858/2007-131-18-asocco",
      "sourceUrl": "https://doi.org/10.5858/2007-131-18-asocco",
      "verified": true
    },
    {
      "title": "Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update",
      "journal": "Archives of Pathology & Laboratory Medicine",
      "year": 2013,
      "citationCount": 1777,
      "doi": "10.5858/arpa.2013-0953-sa",
      "sourceUrl": "https://doi.org/10.5858/arpa.2013-0953-sa",
      "verified": true
    },
    {
      "title": "20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years",
      "journal": "New England Journal of Medicine",
      "year": 2017,
      "citationCount": 1703,
      "doi": "10.1056/nejmoa1701830",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1701830",
      "verified": true
    },
    {
      "title": "Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial",
      "journal": "The Lancet Oncology",
      "year": 2010,
      "citationCount": 1679,
      "doi": "10.1016/s1470-2045(10)70257-6",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(10)70257-6",
      "verified": true
    },
    {
      "title": "2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial",
      "journal": "The Lancet",
      "year": 2007,
      "citationCount": 1504,
      "doi": "10.1016/s0140-6736(07)60028-2",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(07)60028-2",
      "verified": true
    },
    {
      "title": "Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update",
      "journal": "Archives of Pathology & Laboratory Medicine",
      "year": 2018,
      "citationCount": 1431,
      "doi": "10.5858/arpa.2018-0902-sa",
      "sourceUrl": "https://doi.org/10.5858/arpa.2018-0902-sa",
      "verified": true
    },
    {
      "title": "Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update",
      "journal": "Journal of Clinical Oncology",
      "year": 2020,
      "citationCount": 1363,
      "doi": "10.1200/jco.19.02309",
      "sourceUrl": "https://doi.org/10.1200/jco.19.02309",
      "verified": true
    },
    {
      "title": "Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer",
      "journal": "Science Translational Medicine",
      "year": 2015,
      "citationCount": 1107,
      "doi": "10.1126/scitranslmed.aab0021",
      "sourceUrl": "https://doi.org/10.1126/scitranslmed.aab0021",
      "verified": true
    },
    {
      "title": "Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials",
      "journal": "The Lancet Oncology",
      "year": 2017,
      "citationCount": 1090,
      "doi": "10.1016/s1470-2045(17)30777-5",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(17)30777-5",
      "verified": true
    },
    {
      "title": "American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)",
      "journal": "Archives of Pathology & Laboratory Medicine",
      "year": 2010,
      "citationCount": 1033,
      "doi": "10.5858/134.7.e48",
      "sourceUrl": "https://doi.org/10.5858/134.7.e48",
      "verified": true
    },
    {
      "title": "11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial",
      "journal": "The Lancet",
      "year": 2017,
      "citationCount": 998,
      "doi": "10.1016/s0140-6736(16)32616-2",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(16)32616-2",
      "verified": true
    },
    {
      "title": "Aromatase Inhibitors in Breast Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2003,
      "citationCount": 899,
      "doi": "10.1056/nejmra023246",
      "sourceUrl": "https://doi.org/10.1056/nejmra023246",
      "verified": true
    },
    {
      "title": "Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven",
      "journal": "Journal of Clinical Oncology",
      "year": 2008,
      "citationCount": 892,
      "doi": "10.1200/jco.2007.15.9749",
      "sourceUrl": "https://doi.org/10.1200/jco.2007.15.9749",
      "verified": true
    },
    {
      "title": "Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial",
      "journal": "The Lancet",
      "year": 1998,
      "citationCount": 886,
      "doi": "10.1016/s0140-6736(98)85012-5",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(98)85012-5",
      "verified": true
    },
    {
      "title": "American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer",
      "journal": "Archives of Pathology & Laboratory Medicine",
      "year": 2010,
      "citationCount": 886,
      "doi": "10.5858/134.6.907",
      "sourceUrl": "https://doi.org/10.5858/134.6.907",
      "verified": true
    },
    {
      "title": "A \"quickscore\" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.",
      "journal": "Journal of Clinical Pathology",
      "year": 1995,
      "citationCount": 871,
      "doi": "10.1136/jcp.48.9.876",
      "sourceUrl": "https://doi.org/10.1136/jcp.48.9.876",
      "verified": true
    },
    {
      "title": "Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial",
      "journal": "Nature Medicine",
      "year": 2018,
      "citationCount": 860,
      "doi": "10.1038/s41591-018-0009-7",
      "sourceUrl": "https://doi.org/10.1038/s41591-018-0009-7",
      "verified": true
    },
    {
      "title": "Proliferation Marker Ki-67 in Early Breast Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2005,
      "citationCount": 838,
      "doi": "10.1200/jco.2005.07.501",
      "sourceUrl": "https://doi.org/10.1200/jco.2005.07.501",
      "verified": true
    },
    {
      "title": "Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen",
      "journal": "Journal of Clinical Oncology",
      "year": 2009,
      "citationCount": 810,
      "doi": "10.1200/jco.2009.23.1274",
      "sourceUrl": "https://doi.org/10.1200/jco.2009.23.1274",
      "verified": true
    },
    {
      "title": "Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial",
      "journal": "Journal of Clinical Oncology",
      "year": 2005,
      "citationCount": 767,
      "doi": "10.1200/jco.2005.04.005",
      "sourceUrl": "https://doi.org/10.1200/jco.2005.04.005",
      "verified": true
    },
    {
      "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer",
      "journal": "Cancer Research",
      "year": 2016,
      "citationCount": 742,
      "doi": "10.1158/0008-5472.can-15-0728",
      "sourceUrl": "https://doi.org/10.1158/0008-5472.can-15-0728",
      "verified": true
    },
    {
      "title": "Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2011,
      "citationCount": 737,
      "doi": "10.1200/jco.2010.31.2835",
      "sourceUrl": "https://doi.org/10.1200/jco.2010.31.2835",
      "verified": true
    },
    {
      "title": "Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men",
      "journal": "Circulation",
      "year": 2007,
      "citationCount": 736,
      "doi": "10.1161/circulationaha.107.719005",
      "sourceUrl": "https://doi.org/10.1161/circulationaha.107.719005",
      "verified": true
    },
    {
      "title": "Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2010,
      "citationCount": 718,
      "doi": "10.1200/jco.2009.24.4798",
      "sourceUrl": "https://doi.org/10.1200/jco.2009.24.4798",
      "verified": true
    },
    {
      "title": "Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2016,
      "citationCount": 696,
      "doi": "10.1200/jco.2016.67.3061",
      "sourceUrl": "https://doi.org/10.1200/jco.2016.67.3061",
      "verified": true
    },
    {
      "title": "Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group",
      "journal": "JNCI Journal of the National Cancer Institute",
      "year": 2020,
      "citationCount": 670,
      "doi": "10.1093/jnci/djaa201",
      "sourceUrl": "https://doi.org/10.1093/jnci/djaa201",
      "verified": true
    },
    {
      "title": "Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer",
      "journal": "JNCI Journal of the National Cancer Institute",
      "year": 2007,
      "citationCount": 663,
      "doi": "10.1093/jnci/djk020",
      "sourceUrl": "https://doi.org/10.1093/jnci/djk020",
      "verified": true
    },
    {
      "title": "Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics",
      "journal": "JNCI Journal of the National Cancer Institute",
      "year": 2008,
      "citationCount": 651,
      "doi": "10.1093/jnci/djn309",
      "sourceUrl": "https://doi.org/10.1093/jnci/djn309",
      "verified": true
    },
    {
      "title": "Mechanisms of tamoxifen resistance",
      "journal": "Endocrine Related Cancer",
      "year": 2004,
      "citationCount": 634,
      "doi": "10.1677/erc.1.00776",
      "sourceUrl": "https://doi.org/10.1677/erc.1.00776",
      "verified": true
    },
    {
      "title": "Comparison of PAM50 Risk of Recurrence Score With Onco<i>type</i> DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy",
      "journal": "Journal of Clinical Oncology",
      "year": 2013,
      "citationCount": 632,
      "doi": "10.1200/jco.2012.46.1558",
      "sourceUrl": "https://doi.org/10.1200/jco.2012.46.1558",
      "verified": true
    },
    {
      "title": "Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2009,
      "citationCount": 600,
      "doi": "10.1200/jco.2008.20.0642",
      "sourceUrl": "https://doi.org/10.1200/jco.2008.20.0642",
      "verified": true
    },
    {
      "title": "An International Ki67 Reproducibility Study",
      "journal": "JNCI Journal of the National Cancer Institute",
      "year": 2013,
      "citationCount": 588,
      "doi": "10.1093/jnci/djt306",
      "sourceUrl": "https://doi.org/10.1093/jnci/djt306",
      "verified": true
    },
    {
      "title": "Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial",
      "journal": "The Lancet",
      "year": 2013,
      "citationCount": 576,
      "doi": "10.1016/s0140-6736(13)62292-8",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(13)62292-8",
      "verified": true
    },
    {
      "title": "Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2002,
      "citationCount": 572,
      "doi": "10.1200/jco.2002.20.3.751",
      "sourceUrl": "https://doi.org/10.1200/jco.2002.20.3.751",
      "verified": true
    },
    {
      "title": "Analysis of <i>ESR1</i> mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer",
      "journal": "Science Translational Medicine",
      "year": 2015,
      "citationCount": 540,
      "doi": "10.1126/scitranslmed.aac7551",
      "sourceUrl": "https://doi.org/10.1126/scitranslmed.aac7551",
      "verified": true
    },
    {
      "title": "American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer",
      "journal": "PubMed Central",
      "year": 2010,
      "citationCount": 540,
      "doi": null,
      "sourceUrl": "https://openalex.org/W4231018668",
      "verified": true
    },
    {
      "title": "2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial",
      "journal": "The Lancet",
      "year": 2013,
      "citationCount": 498,
      "doi": "10.1016/s0140-6736(13)61094-6",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(13)61094-6",
      "verified": true
    },
    {
      "title": "Current and emerging biomarkers in breast cancer: prognosis and prediction",
      "journal": "Endocrine Related Cancer",
      "year": 2010,
      "citationCount": 488,
      "doi": "10.1677/erc-10-0136",
      "sourceUrl": "https://doi.org/10.1677/erc-10-0136",
      "verified": true
    },
    {
      "title": "Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase",
      "journal": "Journal of Clinical Oncology",
      "year": 2005,
      "citationCount": 485,
      "doi": "10.1200/jco.2005.01.172",
      "sourceUrl": "https://doi.org/10.1200/jco.2005.01.172",
      "verified": true
    },
    {
      "title": "Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data",
      "journal": "The Lancet",
      "year": 2013,
      "citationCount": 476,
      "doi": "10.1016/s0140-6736(13)60140-3",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(13)60140-3",
      "verified": true
    },
    {
      "title": "Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update",
      "journal": "Journal of Clinical Oncology",
      "year": 2023,
      "citationCount": 469,
      "doi": "10.1200/jco.22.02864",
      "sourceUrl": "https://doi.org/10.1200/jco.22.02864",
      "verified": true
    },
    {
      "title": "Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial",
      "journal": "Journal of Clinical Oncology",
      "year": 2008,
      "citationCount": 463,
      "doi": "10.1200/jco.2007.12.9437",
      "sourceUrl": "https://doi.org/10.1200/jco.2007.12.9437",
      "verified": true
    },
    {
      "title": "Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial",
      "journal": "JNCI Journal of the National Cancer Institute",
      "year": 2007,
      "citationCount": 427,
      "doi": "10.1093/jnci/djk050",
      "sourceUrl": "https://doi.org/10.1093/jnci/djk050",
      "verified": true
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:16.000Z",
  "openalexId": "https://openalex.org/A5057689412"
}